Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guilford Pharmaceuticals
Baltimore, Maryland, United Statesguilfordpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Guilford Pharmaceuticals successfully commercialized the GLIADEL® Wafer for brain tumors and AGGRASTAT® Injection for acute coronary syndrome. The company also advanced several novel product candidates into clinical development, including Aquavan Injection in Phase 2 trials for conscious sedation and GPI 1485 in Phase 2 trials for Parkinson's disease. Additional pipeline assets targeted neurological disorders, cancer, and other serious conditions.
- Therapeutic areas
- OncologyCardiovascularEndocrinologyNeurology
- Modalities
- Small moleculesDrug delivery systems (e.g., biodegradable polymer wafers)Biopolymer-based products
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Guilford Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guilford Pharmaceuticals.